Sex-Determining Region Y-Box 2 (SOX2) Expression Predicts Poor Prognosis in Human Ovarian Carcinoma
Jing Zhang, Doo Young Chang, Imelda Mercado-Uribe, Jinsong Liu. The University of Texas MD Anderson Cancer Center, Houston, TX
Background: Sex-determining region Y-box 2 (SOX2) is proposed to be a key transcription factor in embryonic stem cells. The known roles of SOX2 in development and cell differentiation suggest that it is relevant to the aberrant growth of tumor cells. Thus, SOX2 may play an important role in tumor progression. However, its clinical significance in human ovarian carcinoma has been uncertain until recently. The aim of the present study was to clarify the clinical role of SOX2 expression in ovarian carcinoma.
Design: Immunohistochemical staining of 540 human ovarian carcinoma samples for SOX2 was performed using tissue microarray. The associations among SOX2 expression and clinical factors (diagnosis, tumor grade, International Federation of Gynecology and Obstetrics stage, and response to chemotherapy), overall survival, and disease-free survival were analyzed.
Results: We observed SOX2 expression in 15% of the ovarian carcinoma samples. Use of the Fisher exact test and one-way analysis of variance suggested that SOX2 expression was associated with high-grade carcinoma (P = 0.009), especially high-grade serous carcinoma (P = 0.048); International Federation of Gynecology and Obstetrics stage (II-IV, P = 0.005); and malignant mixed müllerian tumors (P = 0.048). SOX2 expression was also associated with decreased disease-free survival durations (P = 0.035; log-rank test).
Conclusions: Our results showed that SOX2 expression is closely related to poor clinical outcome in patients with ovarian cancer. It may be a potential marker of ovarian cancer stem cells related to tumor recurrence, similar to its role in regarding embryonic stem cells.
Category: Gynecologic & Obstetrics
Wednesday, March 21, 2012 1:00 PM
Poster Session VI # 207, Wednesday Afternoon